布地奈德混悬液联合特布他林雾化吸入用溶液和磷酸奥司他韦颗粒治疗婴幼儿病毒性肺炎的临床研究

Clinical trial of budesonide suspension inhalation combined with terbutaline sulfate nebuliser solution and oseltamivir phosphate granules in the treatment of infantile viral pneumonia

目的观察布地奈德混悬液联合特布他林雾化吸入用溶液和磷酸奥司他韦颗粒治疗婴幼儿病毒性肺炎的临床疗效及安全性。方法将100例病毒性肺炎患儿随机分为对照组和试验组,每组50例。对照组给予磷酸奥司他韦颗粒每次15~35 mg,bid,连续口服3 d;试验组在对照组治疗的基础上,给予布地奈德每次0.5 mg+特布他林每次1.0 mg,雾化吸入,bid,连续治疗7 d。比较2组患儿的临床疗效、外周血T淋巴细胞和血清炎症因子水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.00%(46例/50例)和82.00%(41例/50例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的CD3^+分别为(68.77±7.44)%和(61.17±6.84)%,CD4^+分别为(42.08±5.54)%和(36.74±4.99)%,CD8^+分别为(30.78±4.16)%和(38.26±5.32)%,白细胞介素-6分别为(22.18±3.08)和(28.39±3.98)ng·L^-1,白细胞介素-8分别为(8.91±1.21)和(12.77±1.75)ng·L^-1,肿瘤坏死因子-α分别为(28.82±4.04)和(36.52±5.05)ng·L^-1,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有恶心呕吐、头晕和皮疹,对照组的药物不良反应主要有头晕和恶心呕吐。试验组和对照组的总药物不良反应发生率分别为8.00%和6.00%,差异无统计学意义(P>0.05)。结论布地奈德混悬液联合特布他林雾化吸入用溶液和磷酸奥司他韦颗粒治疗婴幼儿病毒性肺炎的临床疗效确切,且不增加药物不良反应的发生率。

Objective To observe clinical efficacy and safety of budesonide suspension combined with terbutaline aerosol inhalation solution and oseltamivir phosphate granules in the treatment of infantile viral pneumonia.Methods A total of 100 patients with infantile viral pneumonia were randomly divided into control and treatment groups with50 cases per group.Control group received oseltamivir phosphate granules 15-35 mg per time,bid,oral administration for 3 d.Treatment group was given budesonide 0.5 mg per time+terbutaline1.0 mg per time,aerosol inhalation therapy,bid,continuous treatment for 7 d,on the basis of control group.The clinical efficacy,levels of peripheral blood T lymphocyte and serum inflammatory factors,and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 92.00%(46 cases/50 cases)and 82.00%(41 cases/50 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:CD3^+were(68.77±7.44)%and(61.17±6.84)%,CD4^+were(42.08±5.54)%and(36.74±4.99)%,CD8^+were(30.78±4.16)%and(38.26±5.32)%,interleukin-6 were(22.18±3.08)and(28.39±3.98)ng·L^-1,interleukin-8 were(8.91±1.21)and(12.77±1.75)ng·L^-1,tumor necrosis factor-αwere(28.82±4.04)and(36.52±5.05)ng·L^-1,the differences were statistically significant(all P<0.05).The adverse drug reactions of treatment group were nausea and vomiting,dizziness and rash,while those in the control group were dizziness and nausea and vomiting.The total incidences of adverse drug reactions in the treatment and control groups were 8.00%and 6.00%without significant difference(P>0.05).Conclusion Budesonide suspension inhalation combined with terbutaline aerosol solution and oseltamivir phosphate granules has a definitive clinical efficacy in the treatment of infantile viral pneumonia,without increasing the incidence of adverse drug reactions.